The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies скачать в хорошем качестве

The standard of care for autoimmune hemolytic anemia and how this may change with novel therapies

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, comments on the current standard of care for autoimmune hemolytic anemia, noting that warm autoimmune hemolytic anemia is typically treated with first-line steroids. In contrast, cold autoimmune hemolytic anemia is addressed with B-cell-directed therapies such as CD20-targeting antibodies. Prof. Jäger highlights that the treatment landscape for these diseases will change with emerging novel agents and therapeutic strategies, and new EHA guidelines will be released to reflect these changes. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.